Beta-Blockers and Bone Health

Overview

About this study

The proposed study will directly examine whether bone mineral density (BMD) and bone microstructure are better preserved among HF patients on chronic β-blockers and account for the reports of decreased fracture.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Olmsted County residents
Age ≥50 yrs
History of HF diagnoses and either:
- have been on β-blockers for at least 1 year
- have not received chronic β-blockers for at least the past 3 years
Age and sex matched controls who do not have HF and who have not received chronic β-blockers for the past 3 years
Eligible women will be postmenopausal for at least 1 year

Exclusion Criteria:

Current or past history of malignancy that has required chemotherapy
Chronic renal insufficiency (GFR<30)
Bilateral hip replacements/pinning
History of current or past chronic glucocorticoid use (>3 months)
On pharmacologic doses of thyroid replacement
Current users of teraparatide, denosumab, oral or IV bisphosphonates, calcitonin, oral hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), aromatase inhibitors in past 12 months, or androgen blockers
Subjects who are not ambulatory

More information

Publications

Publications are currently not available

Clinical Trials